Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893626 | 1.00 | LMNA (0.41) | LMNADNM1TSHRTHRBPLA2G1B | |
| SCHEMBL37787 | 1.00 | LMNA (0.41) | LMNADNM1TSHRTHRBPLA2G1B | |
| SCHEMBL29209175 | 1.00 | LMNA (0.41) | LMNADNM1TSHRTHRBPLA2G1B | |
| SCHEMBL28664577 | 1.00 | LMNA (0.41) | LMNADNM1TSHRTHRBPLA2G1B | |
| SCHEMBL22986852 | 1.00 | LMNA (0.41) | LMNADNM1TSHRTHRBPLA2G1B | |
| SCHEMBL4798727 | 1.00 | LMNA (0.41) | LMNADNM1TSHRTHRBPLA2G1B | |
| SCHEMBL24990076 | 1.00 | LMNA (0.41) | LMNADNM1TSHRTHRBPLA2G1B | |
| SCHEMBL4797069 | 1.00 | LMNA (0.41) | LMNADNM1TSHRTHRBPLA2G1B | |
| SCHEMBL14840061 | 1.00 | LMNA (0.41) | LMNADNM1TSHRTHRBPLA2G1B | |
| SCHEMBL14840100 | 1.00 | LMNA (0.41) | LMNADNM1TSHRTHRBPLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110461355-A | The composition of Immune-enhancing effect and application thereof comprising immunoregulation agent and cationic-liposome | EYEGENE INC | 2019-11-15 | — | — | CN | claimed |
| CN-115052615-A | Peptide conjugates and methods of use | 斯克利普斯研究所 | 2022-09-13 | — | — | CN | disclosed |
| EP-3777891-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | Institute of Basic Medical Sciences, Chinese Academi of Medical Sciences (CN) | 2021-02-17 | — | — | EP | disclosed |
| CN-112105343-A | anti-PD-1 antibody compositions | 辉瑞公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-111050740-A | Composition for caring hair | 株式会社爱茉莉太平洋 | 2020-04-21 | — | — | CN | disclosed |
| CN-105521491-B | Concentrated protein formulations and uses thereof | 西托戴恩有限公司 | 2020-03-24 | — | — | CN | disclosed |
| US-9809717-B2 | Antimicrobial-coated medical articles | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2576471-B1 | ANTIMICROBIAL COATED MEDICAL ARTICLES | 3M INNOVATIVE PROPERTIES CO (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2576472-B1 | ANTIMICROBIAL COATINGS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20150175812-A1 | ANTIMICROBIAL COATINGS | 3M INNOVATIVE PROPERTIES CO (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150024019-A1 | ANTIMICROBIAL-COATED MEDICAL ARTICLES | 3M INNOVATIVE PROPERTIES COMPANY | 2015-01-22 | — | — | US | disclosed |
| EP-2576472-A2 | ANTIMICROBIAL COATINGS | 3M Innovative Properties Company (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2576471-A2 | ANTIMICROBIAL COATED MEDICAL ARTICLES | 3M Innovative Properties Company (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120015002-A1 | ANTIMICROBIAL COATINGS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-01-19 | — | — | US | disclosed |
| WO-2011150001-A2 | ANTIMICROBIAL COATINGS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011150103-A2 | ANTIMICROBIAL–COATED MEDICAL ARTICLES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015002-A1 | ANTIMICROBIAL COATINGS | ARG1, CAPG, CLSPN | LMNA 4435/4885DNM1 901/4885TSHR 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.